Enanta says Phase 2 trial shows zelicapavir reduces RSV symptom duration, hospitalization

Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc.

ENTA

0.00
  • Enanta Pharmaceuticals flagged new Phase 2 data for zelicapavir in respiratory syncytial virus, with results set for presentation May 19, 2026 at American Thoracic Society International Conference.
  • Trial readout showed zelicapavir shortened symptom duration, with fewer hospitalizations versus placebo.
  • Separate preclinical posters scheduled for same meeting highlight EPS-3903, an oral STAT6 inhibitor that reduced Th2-driven inflammation in an asthma mouse model.
  • Additional data point to lung-focused drug distribution for EPS-3903, with low drug-drug interaction potential aimed at supporting asthma development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enanta Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260504237451) on May 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.